MARKET WIREYahoo Finance • 14h ago
Bio-Techne Corp (TECH) Stock ForecastsYahoo Finance report covering Bio-Techne Corp (TECH) market action, institutional positioning, and fundamental catalysts.
Why TECH Stock slipped -0.07% Today — RQD Quant Desk Flash
$72.66 -0.07% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $72.83
Bio-Techne Corp (TECH) earns a Roarable Rating of B (Buy) with 72/100 RQD Confidence. High-quality cash engine (65% profit margin, 3% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.
ROARABLE B • BUY
Cap $11.40B
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on TECH Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is TECH stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, Bio-Techne Corp (NASDAQ: TECH) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 72/100 at a spot price of $72.66 (-0.07% 1D, market cap $11.40B). Pillar breakdown: Fundamental Cash Engine 14/20, Institutional 13F & Options Flow 17/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 14/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, TECH ranks #65 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does TECH compare to TWST and RGEN in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), TECH carries a Roarable B (72/100 RQD), trailing P/E of 155.3x, gross margin of 64.8%, and ROIC of 3.4%. By comparison, TWST (Twist Bioscience Corporation) holds a D+ grade (52/100 RQD, P/E N/A, ROIC -11.7%, cap $11.50B) and RGEN (Repligen Corporation) posts a C grade (64/100 RQD, P/E N/A, ROIC 2.3%, cap $10.69B). Among the 5-stock peer group, QGEN leads on earnings multiple (24.4x) while QGEN leads on capital efficiency (8.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for TECH?
▼
Per TECH's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0000842023), Bio-Techne Corp generated $1.22B in revenue (+5.2% YoY), $73.4M in net income, and $256.6M in free cash flow against $2.52B in total assets and $590.3M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $72.83 (+0.23%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 14/20 (B-) • 21% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 72/100 (B) historically ranked in the Top 13% of excess returns over the next 90 days (+7.0% avg 90D alpha vs SPY • 68.7% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERBUY • B
3-of-3 JEV AI Jury Bullish
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw C+ · Rk B+
Each axis scored 0–20
12M PRICE TARGET CONE+6.3% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for TECH)Realized 20D OHLCV Swing Band: ±1.8%
Deterministic 5-Pillar Attribution (72/100 Composite)
🔍 WHY TECH SCORES 72/100 (B) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+18/20 pts (25% of score)
Altman Z-Score 7.12 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 8/9
▲ #2 Bullish Driver: Whale & Options Positioning+17/20 pts (24% of score)
20D Institutional Volume Accumulation (±1.8% realized swing band)
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution9/20 pts (-11 pt drag)
Disciplined Float (-0.40% YoY Shares) & executive Form 4 sales trim 11 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C+$72.48+0.1% Next Q
64
Q2 (-2Q)Grade B-$72.58+0% Next Q
67
Q3 (-1Q)Grade B-$72.60+0.1% Next Q
69
CurrentGrade B$72.66+7% Hist 90D α
72
Trajectory: C+ (64) → B (72)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER
⚔️ Adversarial Opposing Case: Why the TECH Bull Thesis Could Fail
Even with a 72/100 (B) score, TECH faces multiple-compression risk if 155.3x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
⚠️ Forensic Kill-Switch #1
Company executives have done more routine share selling than personal cash buying lately.
⚠️ Forensic Kill-Switch #2
Priced at 155x earnings—high expectations leave less room for a lukewarm quarter.
⚠️ Forensic Kill-Switch #3
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($72.47) or 200D SMA ($63.19) invalidates the momentum regime and cuts Target Base ($77.24) toward Bear Floor ($59.58).
🎲 LIVE PREDICTION MARKET ODDS TIED TO $TECH• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “TECH Beats Next Quarter EPS Consensus (Dec 28, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why TECH Stock slipped -0.07% Today — RQD Quant Desk Flash
Bio-Techne Corp (TECH) slipped -0.07% to $72.66, trading at 99% of its 52-week range ($43.2 – $72.75). High-quality cash engine (65% profit margin, 3% return on capital) with steady institutional support.
- ▸Technical Tape: Trading at 99% of its 52-week range ($43.2 – $72.75) with RSI-14 at 59.3 (BULLISH MOMENTUM).
- ▸Volatility Profile: Historical 20-day realized swing band of ±1.8% around $72.66 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable B (Buy) backed by 64.8% gross margin and $256.6M annual free cash flow.
Live TECH Headlines & Catalysts
MARKET WIREMoomoo • 17h ago
Bio-Techne (TECH) Stock Forecast & Analyst RatingsMoomoo report covering Bio-Techne Corp (TECH) market action, institutional positioning, and fundamental catalysts.
MARKET WIRESimply Wall St • 20h ago
Bio-Techne (Nasdaq:TECH) - Stock AnalysisSimply Wall St report covering Bio-Techne Corp (TECH) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingView • 23h ago
Bio-Techne's Q1 Earnings on Deck: What's in Store for the Stock?TradingView report covering Bio-Techne Corp (TECH) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 1d ago
What You Need to Know Ahead of Bio-Techne’s Earnings ReleaseYahoo Finance report covering Bio-Techne Corp (TECH) market action, institutional positioning, and fundamental catalysts.
MARKET WIREThe Globe and Mail • 1d ago
1 Unpopular Stock That Should Get More Attention and 2 We QuestionThe Globe and Mail report covering Bio-Techne Corp (TECH) market action, institutional positioning, and fundamental catalysts.
RISK WATCHStock Titan • 1d ago
Five executives are approved for conditional retention cash at Bio-Techne (TECH).Stock Titan report covering Bio-Techne Corp (TECH) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Traders Daily • 1d ago
How Bio-techne Corp (TECH) Affects Rotational Strategy TimingStock Traders Daily report covering Bio-Techne Corp (TECH) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo • 15h ago
Stocks rebound as oil prices sink, Anthropic releases Q3 financials: AlphaCheckStocks rebounded on Monday following a brutal sell-off in tech.
RISK WATCHYahoo • 4d ago
Alphabet tumbles, software and cybersecurity stocks sink as earnings disappoint: AlphaCheckTech stocks declined on Thursday as shares of Alphabet plunged and software and cybersecurity stocks tumbled.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk
Scheduled RQD Strong Buys & Whale Accumulation Briefing (TECH Tape Review)
- ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
- ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
- ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
TECH // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +32.74%⚡ TESTING RESISTANCE
2026-11-02O $72.69H $72.71L $72.66C $72.66VOL 2.89M
RES: $72.79SMA50: $72.47SMA200: $63.19
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
TECH Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
48.0%/yr Implied 5Y Growth
vs. +5.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on TECH today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for TECH. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for TECH today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (TECH)
Health Care Rank #65 of 1016
⚔️ TWST vs TECH Full Matrix →
1. Head-to-Head Health Care Peer Comparison (TECH vs. TWST, RGEN, QGEN, KYMR)
Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Bio-Techne Corp (TECH) ranks #65 by composite RQD confidence (72/100, grade B) and #98 by equity capitalization ($11.40B). Within this direct 5-issuer industry benchmark cohort, QGEN leads on earnings valuation at 24.4x trailing P/E, while QGEN leads on capital efficiency and profitability with 8.0% ROIC and 62.2% gross margin. TECH currently leads its immediate peer cohort in composite quantitative strength at 72/100 (B).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| TECH
ACTIVE
Bio-Techne Corp | B | 72/100 | 155.3x | 64.8% | 3.4% | -0.07% | $11.40B | Benchmark Subject |
| TWST Twist Bioscience Corporation | D+ | 52/100 | — | 94.2% | -11.7% | -11.92% | $11.50B | /twst-vs-tech → |
| RGEN Repligen Corporation | C | 64/100 | — | 88.2% | 2.3% | -6.20% | $10.69B | /rgen-vs-tech → |
| QGEN Qiagen N.V. | B- | 71/100 | 24.4x | 62.2% | 8.0% | -0.24% | $10.37B | /qgen-vs-tech → |
| KYMR Kymera Therapeutics Inc. | D | 50/100 | 32.7x | — | -21.4% | +3.29% | $10.19B | /kymr-vs-tech → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-06-30 • CIK 0000842023In its most recent audited fiscal period (FY2025, filed 2025-06-30), Bio-Techne Corp (TECH) reported GAAP revenue of $1.22B (+5.2% vs. FY2024 revenue of $1.16B , and +7.3% cumulative change since FY2023) , GAAP net income of $73.4M, operating cash flow of $287.6M, and free cash flow of $256.6M (+8.7% YoY). On the balance sheet, TECH closed FY2025 with $2.52B in total assets against $590.3M in total debt (Altman Z-Score: 7.12, Piotroski F-Score: 8/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-06-30 | $1.22B | $73.4M | $287.6M | $256.6M | $2.52B | $590.3M |
| FY2024 (FY) | 2024-06-30 | $1.16B | $168.1M | $299.0M | $236.1M | $2.67B | $624.9M |
| FY2023 (FY) | 2023-06-30 | $1.14B | $285.3M | $254.4M | $203.2M | $6.27B | $1.47B |
3. TECH Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs TECH stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, Bio-Techne Corp (NASDAQ: TECH) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 72/100 at a spot price of $72.66 (-0.07% 1D, market cap $11.40B). Pillar breakdown: Fundamental Cash Engine 14/20, Institutional 13F & Options Flow 17/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 14/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, TECH ranks #65 in composite RQD confidence.
How does TECH compare to TWST and RGEN in the Health Care sector?
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), TECH carries a Roarable B (72/100 RQD), trailing P/E of 155.3x, gross margin of 64.8%, and ROIC of 3.4%. By comparison, TWST (Twist Bioscience Corporation) holds a D+ grade (52/100 RQD, P/E N/A, ROIC -11.7%, cap $11.50B) and RGEN (Repligen Corporation) posts a C grade (64/100 RQD, P/E N/A, ROIC 2.3%, cap $10.69B). Among the 5-stock peer group, QGEN leads on earnings multiple (24.4x) while QGEN leads on capital efficiency (8.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for TECH?
Per TECH's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0000842023), Bio-Techne Corp generated $1.22B in revenue (+5.2% YoY), $73.4M in net income, and $256.6M in free cash flow against $2.52B in total assets and $590.3M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is TECH trading relative to its 50-day, 200-day, and 52-week technical levels?
TECH last traded at $72.66 (-0.07% on volume of 2,565,964 shares), positioning the stock +0.26% above its 50-day simple moving average ($72.47) and +14.99% above its 200-day simple moving average ($63.19). Across its 52-week range of $43.20 to $72.75, TECH sits at the 99.7% percentile with a 14-day RSI of 59.3 (BULLISH MOMENTUM) and an implied next-earnings move of ±1.8% ($71.35 to $73.97).
TECH Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is TECH stock moving today?
Why TECH Stock slipped -0.07% Today — RQD Quant Desk Flash. High-quality cash engine (65% profit margin, 3% return on capital) with steady institutional support.
ROARABLE RATING BRIEF • RQD 72/100 (B)
✓ STAGE-C NUMBER FIREWALL VERIFIED
TECH — Bio-Techne Corp: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:15:54Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, TECH scores 72 out of 100 (letter grade B, verdict "Roarable Buy — Good Risk/Reward"). The five pillars are:
- Fundamental Cash Engine: 14 / 20 — ROIC of 3.4% and FCF yield of 2.25%. Returns on invested capital are modest relative to the stock's multiples, which means the cash generation case is present but not strong on a yield basis.
- Whale 13F Flow: 17 / 20 — Institutional accumulation and options positioning are the highest-scoring pillar, indicating the strongest support signal in the rating. Holder detail itself is not available in source data.
- Insider Conviction: 9 / 20 — The lowest pillar, reflecting weaker SEC Form 4 and Congressional PTR cluster flow. For a prospective investor, this is the least-supported part of the thesis.
- Macro Regime Fit: 14 / 20 — Beta of 0.88 indicates below-market sensitivity to broad moves, with sector sensitivity noted in the rating.
- Forensic Balance Sheet: 18 / 20 — Altman Z of 7.12, Piotroski F of 8/9, and Debt/Equity of 0.25 make this the strongest pillar and the main defensive argument.
Investor implications: the rating reflects a balance-sheet-strong, institutionally-supported profile paired with rich valuation (P/E TTM of 155.3, EV/EBITDA of 91.3) and thin cash returns (ROIC 3.4%). Upside depends on earnings growth catching up to the multiples; the valuation tradeoff is the central risk. This is an analytical summary, not personalized advice.
Snapshot
Business
Bio-Techne Corp (TECH) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Biological Products (No Diagnostic Substances) industry. Per the profile, the company has a market capitalization of $11.4B. Products, customer base, and revenue model details are not available in source data.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $1219.6M | $102.3M | $73.4M | N/A | $256.6M | $172.9M | $590.3M |
| FY 2024 | $1159.1M | $206.7M | $168.1M | N/A | $236.1M | $177.5M | $624.9M |
| FY 2023 | $1136.7M | $298.9M | $285.3M | N/A | $203.2M | N/A | $1467.5M |
Per the SEC financials, revenue rose from $1136.7M (FY 2023) to $1219.6M (FY 2025), while operating and net income declined over the same span. Per the market data, gross margin is 64.8%, operating margin 8.4%, and net margin 6%. Per the Roarable RQD rating, the Altman Z-Score is 7.12 and the Piotroski F-Score is 8/9. Debt/Equity is 0.25 and reported debt fell from $1467.5M to $590.3M across the periods shown.
Open Questions
- What drives revenue growth given the decline in operating and net income from FY 2023 to FY 2025?
- What explains the gap between the 155.3 P/E (TTM) and the 0.47 EPS, and what is the earnings trajectory implied by the 140 forward P/E?
- Which institutional holders account for the Whale 13F Flow score, and what is the size and direction of their positions?
- What are the specific Q1 earnings date, expectations, and guidance referenced in the news wire?
- Why are EPS values for all reported periods listed as N/A, and what is the cash balance for FY 2023?
TECH Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Bio-Techne Corp (TECH) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo Finance • 14h ago
Bio-Techne Corp (TECH) Stock Forecasts Yahoo Finance report covering Bio-Techne Corp (TECH) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Moomoo • 17h ago
Bio-Techne (TECH) Stock Forecast & Analyst Ratings Moomoo report covering Bio-Techne Corp (TECH) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Simply Wall St • 20h ago
Bio-Techne (Nasdaq:TECH) - Stock Analysis Simply Wall St report covering Bio-Techne Corp (TECH) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingView • 23h ago
Bio-Techne's Q1 Earnings on Deck: What's in Store for the Stock? TradingView report covering Bio-Techne Corp (TECH) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 1d ago
What You Need to Know Ahead of Bio-Techne’s Earnings Release Yahoo Finance report covering Bio-Techne Corp (TECH) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE The Globe and Mail • 1d ago
1 Unpopular Stock That Should Get More Attention and 2 We Question The Globe and Mail report covering Bio-Techne Corp (TECH) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH Stock Titan • 1d ago
Five executives are approved for conditional retention cash at Bio-Techne (TECH). Stock Titan report covering Bio-Techne Corp (TECH) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Traders Daily • 1d ago
How Bio-techne Corp (TECH) Affects Rotational Strategy Timing Stock Traders Daily report covering Bio-Techne Corp (TECH) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
TECH Bull vs. Bear Conversation Board — What's Your Call at $72.66?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON TECH 🐻 33% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk 🐂 BULLISH
🎯 Target: $85.80 (+18.0%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is TECH (B • RQD 72/100) a Buy at $72.71?
Welcome to the TECH (Bio-Techne Corp) Roar Pit. Current RQD Composite is 72/100 (Roarable Buy — Good Risk/Reward) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on valuation multiple compression (155.3x trailing P/E). Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
SH ShortSeller_Dan Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $57.44 (-21.0%)
Spot @ $72.71 Pump the brakes on TECH — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on TECH, but look at what you are paying: 155.3x trailing P/E with 64.8% gross margins. Unless Bio-Techne Corp expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
TA TapeReader_Pro Verified K Arena Trader 🐂 BULLISH
🎯 Target: $82.89 (+14.0%)
Spot @ $72.71 TECH cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on TECH, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $72.71 (52-wk range $43.20 - $72.75), any beat on forward guidance forces shorts and underweight funds to chase.